Cerner is leveraging its recent acquisition of Kantar Health to create a new business unit targeting companies with clinical trials, the company said on Tuesday.
Called Enviza, the new division will sell data and research services to facilitate clinical research conducted by life science companies. The unit will bring together Cerner’s data business with the life sciences expertise of Kantar Health, which Cerner purchased for $ 375 million through a deal reached in April.
Enviza’s customers will primarily be life science companies and healthcare providers, said Mike Kelly, global director of Enviza and former president and COO of Kantar Health. Providers participating in Cerner’s Learning Health Network can access the electronic health records database and analysis tools free of charge. Companies developing new drugs and other therapies will provide the bulk of Enviza’s revenue, Kelly said.
“There is a strong desire in life sciences to have access to real world data,” said Kelly. Life science companies using Enviza’s data and services will be able to accelerate new therapies through scientific and regulatory processes, he said.
Download the Modern Healthcare app to stay up to date with industry news.
Enviza will sell access to anonymized patient information from EHRs and provide research services to pharmaceutical and biotechnology companies. The new division is set up to help customers collect relevant data, set up trials and submit safety and efficacy results to regulators.
Cerner’s Learning Health Network is the repository of anonymized patient records collected from 76 participating health systems. Enviza customers will be able to use this data to locate patients who may be suitable for clinical trials. Enviza will then give Cerner supplier customers the opportunity to contact patients and invite them to participate in research studies.
Electronic health record providers such as Cerner have sought to diversify their businesses beyond selling computer systems by offering tools and services to help providers and life science companies use patient data. for their operations.
Cerner identified “data as a service” as an opportunity for growth. Prior to creating Enviza, the company implemented this by creating the Learning Health Network and investing in Elligo Health Research, a startup focused on clinical trials.
“Cerner is definitely considering monetizing the data in its EHR platform,” said Paddy Padmanabhan, CEO of Damo Consulting. “It’s a big frontier in unlocking patient data. “
Last year, Epic Systems launched Cosmos, an anonymized EHR database collected from the Epic Health Research Network. The Veradigm Payer and Life Sciences division of Allscripts also sells vendor analysis tools and anonymized patient data for biopharmaceutical researchers.
Healthcare providers have made inroads into similar industries that also compile and sell patient data. Companies like the hospital-backed Truveta have garnered millions of dollars in investments.
Cerner reported second-quarter revenue of $ 1.5 billion in July, up 9.5% from $ 1.3 billion from the previous year period, as the company identified as the quarter most affected by the COVID-19 pandemic. Cerner’s operating profit for the second quarter of 2021 fell 66% to $ 49.6 million, the company said. Cerner is due to report its third quarter financial results on Friday.